Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Pliant Therapeutics Pauses Enrollment And Dosing In BEACON-IPF Trial, Stock In Freefall
Pliant Therapeutics Inc. (PLRX) suffered a major blow on Friday, with its shares tumbling nearly 35% in regular trading and plunging ...
Business Wire4d
Crown Laboratories Completes Acquisition of Revance Therapeutics
The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company ...
Yale Daily News6d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
Hosted on MSN6d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.